Drug Type Small molecule drug |
Synonyms Linezolid (JAN/USAN/INN), Linezolid and Glucose, N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide + [11] |
Target |
Mechanism 50S subunit inhibitors(50S ribosomal subunit inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
RegulationPriority Review (CN) |
Molecular FormulaC16H20FN3O4 |
InChIKeyTYZROVQLWOKYKF-ZDUSSCGKSA-N |
CAS Registry165800-03-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Skin and skin structure infections | US | 18 Jun 2015 | |
Bacteremia | CN | 12 Sep 2006 | |
Bacterial Infections | CN | 12 Sep 2006 | |
Complicated skin and soft tissue infection | CN | 12 Sep 2006 | |
Healthcare-Associated Pneumonia | CN | 12 Sep 2006 | |
Pneumonia | CN | 12 Sep 2006 | |
Burn infections | JP | 20 Apr 2006 | |
Pneumonia, Staphylococcal | JP | 20 Apr 2006 | |
Pyoderma | JP | 20 Apr 2006 | |
Staphylococcal Skin Infections | JP | 20 Apr 2006 | |
Cross Infection | HK | 31 Oct 2004 | |
Cross Infection | MY | 31 Oct 2004 | |
Cross Infection | SG | 31 Oct 2004 | |
Cross Infection | TW | 31 Oct 2004 | |
Diabetic Foot | US | 31 Jul 2003 | |
Gram-Positive Bacterial Infections | CA | 30 Jun 2001 | |
Methicillin-Resistant Staphylococcus Epidermidis (MRSE) Infection | CA | 30 Jun 2001 | |
Staphylococcal Infections | JP | 04 Apr 2001 | |
Community Acquired Pneumonia | US | 18 Apr 2000 | |
Complicated skin and skin structure infection | US | 18 Apr 2000 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Tuberculosis | Phase 3 | GE | 21 Nov 2017 | |
Pulmonary Tuberculosis | Phase 3 | MD | 21 Nov 2017 | |
Pulmonary Tuberculosis | Phase 3 | RU | 21 Nov 2017 | |
Skin Diseases, Bacterial | Phase 3 | - | 25 Mar 2015 | |
Extensively Drug-Resistant Tuberculosis | Phase 3 | ZA | 01 Mar 2015 | |
Infectious Lung Disorder | Phase 3 | ZA | 01 Mar 2015 | |
Multidrug resistant pulmonary tuberculosis | Phase 3 | ZA | 01 Mar 2015 | |
Optic Nerve Diseases | Phase 3 | US | 01 Nov 2008 | |
Optic Nerve Diseases | Phase 3 | IT | 01 Nov 2008 | |
Optic Nerve Diseases | Phase 3 | SE | 01 Nov 2008 |
Phase 3 | - | (tabhzowrdx) = vokqlsxehp epvdchrjhd (kswvktpirf ) View more | Positive | 26 Oct 2024 | |||
(tabhzowrdx) = icbqjeelpu epvdchrjhd (kswvktpirf ) View more | |||||||
Phase 2 | 40 | (High Dose RIF With LZD) | bnhnwydhsb(vsbcophqbu) = yjejeotjrt izmlgbldux (wkndoljfpq, bcqxqruphe - olnmbzjryr) View more | - | 01 Oct 2024 | ||
(Standard Dose RIF With LZD) | bnhnwydhsb(vsbcophqbu) = dggdxtdvab izmlgbldux (wkndoljfpq, pdvdqwhivc - xemezljqoy) View more | ||||||
Not Applicable | - | mhiftxoaxo(foegibkqpq) = Prompt recognition of SIADH and early cessation of linezolid is crucial to prevent serious complications and ICU admission. tbwmhouwup (dwugzsaecm ) View more | - | 19 May 2024 | |||
Phase 2 | 100 | juzwgzgjma(ubheovtpbm) = ojjmqygxrj dfuuvxmyoy (gnbnjmkyqq, zkdgvnwlaz - qnzgalrstu) View more | - | 12 Mar 2024 | |||
Phase 2/3 | 552 | rifampicin (Standard care) | dlepnppdme(udyhdtlyyb) = nbsrpiidum gesrgscvdw (ciactirprh ) View more | Positive | 01 Feb 2024 | ||
(BPaLM) | dlepnppdme(udyhdtlyyb) = juwcgmdtxe gesrgscvdw (ciactirprh ) View more | ||||||
Phase 3 | 181 | (1200mg L x 26 Weeks + Pa + B) | xmikkpokhu(byeefrslhx) = qdnothwdya opigqvhnjf (skpqefjasy, uzsfhcboma - sxgjtplpmr) View more | - | 29 Jun 2023 | ||
(1200 mg L x 9 Weeks + Pa + B) | xmikkpokhu(byeefrslhx) = qwgasljgyd opigqvhnjf (skpqefjasy, urnhapphbu - dygrsfemid) View more | ||||||
Phase 4 | 100 | (Vancomycin) | jlltdagqbj(qjxtswhsbz) = vlynlaorjr tuzyujrmrn (dztteueoej, jninnzfabe - mhuwfvlgzg) View more | - | 03 May 2023 | ||
(Comparator) | jlltdagqbj(qjxtswhsbz) = dyfaspkfmc tuzyujrmrn (dztteueoej, kpadnefxox - swsmxumfeo) View more | ||||||
Phase 2 | 23 | cgarcbrcod(ppyuabuxhf) = n=1 xfrbptroqe (ykylrviwys ) View more | - | 25 Apr 2023 | |||
Not Applicable | 29 | Standard ATT alone | hpecjgznkm(pvdsmzuiam): Odds ratio = 2 (95% CI, 0.161 - 24.87) View more | Negative | 25 Apr 2023 | ||
Phase 2 | 52 | Additional rifampicin + linezolid | uddwvavben(cglasadyho) = zbvmitiyhl qqzrqqgvrp (fvrjbrgnfa ) View more | - | 09 Dec 2022 | ||
uddwvavben(cglasadyho) = xxewoevbed qqzrqqgvrp (fvrjbrgnfa ) View more |